Viatris is the deep-value play in global generic pharma, trading at just 6.1x forward earnings and a 0.15 PEG — among the cheapest large-cap healthcare names available. Formed from the 2020 Mylan-Upjohn combination, the company has spent four years reshaping its portfolio, divesting non-core assets, and deleveraging. The result: four consecutive EPS beats, a nearly 3% dividend yield, and a business built on inelastic prescription-drug demand that holds up across economic cycles. At $16.33 the stock sits above all three EMAs with RSI at a comfortable 56 — an actionable entry, not an extended chase. The trailing PE shows N/A due to non-cash impairments, but adjusted earnings tell a very different story.
Viatris Inc. is a global healthcare company formed in November 2020 from the combination of Mylan N.V. and Upjohn, Pfizer's established-brands division. Headquartered in Canonsburg, Pennsylvania, the company employs approximately 30,000 people and operates across four segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets.
The portfolio spans prescription brand drugs, generic drugs, complex generics, and biosimilars. Key brands include household names like Lipitor, Lyrica, Celebrex, Viagra, Creon, EpiPen, Norvasc, Effexor, Zoloft, and Xanax — a diversified basket of off-patent drugs with deeply entrenched prescribing patterns. The moat is scale and inelastic demand: patients need these medications regardless of economic conditions, and Viatris's global manufacturing and distribution network creates barriers to entry that smaller generic players cannot replicate.
| Metric | Value | Signal |
|---|---|---|
| Forward P/E | 6.13x | Deep value — bottom decile healthcare |
| PEG Ratio | 0.15 | Outstanding growth-adjusted value |
| EPS Q1 2026 (adj.) | $0.59 | Beat $0.50 est. · +18% |
| EPS Q4 2025 (adj.) | $0.57 | Beat $0.53 est. · +7.5% |
| EPS Q3 2025 (adj.) | $0.67 | Beat $0.62 est. · +8.1% |
| EPS Q2 2025 (adj.) | $0.62 | Beat $0.56 est. · +10.7% |
| EV/EBITDA | 7.50x | Cheap vs. pharma median ~12x |
| EV/Revenue | 2.12x | Reasonable for branded generics |
| Price / Book | 1.30x | Near tangible asset value |
| Dividend Yield | 2.99% | Active dividend — income component |
| Market Cap | $19.02B | Large-cap — institutional liquidity |
| RSI (14) | 56.2 |
| EMA 20 | $15.97 |
| EMA 50 | $15.67 |
| EMA 200 | $13.38 |
| MACD | 0.017 |
| Signal | 0.020 |
| ATR (14) | $0.48 |
Viatris is a large-cap generic pharma with inelastic demand and a strong earnings beat streak. The principal risks are balance-sheet leverage from the Mylan-Upjohn merger, generic drug pricing pressure, and regulatory headline risk — not existential threats to a $19B company with diversified global revenues.
VTRS trades at 6.1x forward earnings because the market is pricing in the legacy goodwill impairments and debt from the Mylan-Upjohn merger. The trailing PE shows N/A (loss), which scares off screens. But adjusted EPS tells a different story: four consecutive beats, a 0.15 PEG, and a nearly 3% dividend — the market is discounting the past while the earnings power is improving. The trade monetizes this gap between reported optics and underlying cash-generation quality.
Deep value entry on a global generic pharma giant trading at 6.1x forward earnings and a 0.15 PEG with four consecutive EPS beats. The stock is above all three EMAs with a comfortable RSI of 56, not extended. Entry zone $16.00–$16.65 captures the current consolidation near the 52-week high. Stop at $15.60 sits below EMA20 support ($15.97). TP1 at $17.80 targets a breakout above the 52-week high ($17.53) with room for price discovery. Russell reconstitution on Monday could drive passive index inflows. Inelastic demand from branded generics provides downside protection in any macro regime. Ideal for ERO (Expansion / Recovery / Overweight) regime allocation.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, SEC EDGAR, and public market data. Accuracy is not guaranteed.